Does Humana Cover Wegovy? 2026 Coverage Rules, Prior Authorization, and Costs
By The RX Index Editorial Team
Published: · Last reviewed:
Last verified: May 15, 2026. Sources checked this week: Humana's 2026 Medicare drug list, Humana's prior authorization page, Humana's Wegovy clinical policy (PG194), CMS Medicare GLP-1 Bridge FAQ, FDA prescribing information, KFF Medicaid GLP-1 coverage analysis, NovoCare price guide, Ro pricing page, and Sesame Care's weight-loss program page. — The RX Index editorial team.
Some provider links in this guide are affiliate links. The RX Index may earn a commission at no extra cost to you. Our recommendation order is based on verified fit for this specific coverage question, not on commission.
The short answer (read this first)
Does Humana cover Wegovy? It depends on your plan, why your doctor prescribed it, and the date.
If you have Humana commercial insurance (employer or marketplace), Wegovy for weight loss is usually excluded unless your employer added a weight-management benefit.
If you have Humana Medicare (Medicare Advantage with drug coverage or standalone Part D), ordinary Part D generally cannot cover Wegovy for weight loss. But Wegovy has two non-weight-loss FDA-approved uses that Medicare can cover: cardiovascular risk reduction for adults with established heart disease, and MASH (a serious liver condition) for adults with moderate-to-advanced fibrosis. Either pathway needs prior authorization.
If you have Humana Healthy Horizons Medicaid, your coverage depends on which state you live in. KFF found only 13 state Medicaid programs covered GLP-1s for obesity as of January 2026.
And here's the part most articles miss: starting July 1, 2026, eligible Medicare Part D members can get Wegovy for weight management at a $50/month copay through the CMS Medicare GLP-1 Bridge — and Humana itself is the company CMS hired to process those claims nationwide.
Your Humana situation → your fast answer
| If you have… | Does Humana cover Wegovy? |
|---|---|
| Humana commercial or employer plan | Usually no for weight loss. Some employers add coverage. Check MyHumana for your exact plan. |
| Humana Medicare Advantage with Rx (MAPD) | Not for weight loss alone. Possible yes for cardiovascular risk reduction (heart disease + BMI ≥27) or MASH. Starting July 1, 2026: $50/month through the Medicare GLP-1 Bridge. |
| Humana standalone Part D (PDP) | Same as MAPD above. |
| Humana Healthy Horizons (Medicaid) | Depends on your state. Coverage is state-PDL controlled. |
| Humana Medigap (Medicare Supplement) | Medigap doesn't cover prescription drugs. Your standalone Part D plan controls coverage. |
| Humana denied you already | The next step depends on why. See our denial decision tree below. |
Want a personal answer?
Find your Humana Wegovy coverage path →Answer 5 quick questions — we'll show you the exact route, including the script to read to Humana and your prior authorization checklist.
Why a Wegovy claim with Humana can fail before it ever reaches a normal review
Humana has used point-of-sale “medically accepted indication” edits on several GLP-1 drugs since June 2023. Those edits screen the diagnosis or ICD-10 code at the pharmacy counter and can reject claims that don't match a covered use. Wegovy has its own clinical policy (Humana PG194) that controls non-weight-loss coverage.
What this means for you: if your plan excludes weight-loss drugs as a benefit category and your prescription is coded for weight loss, you can hit a denial without ever getting a real medical review. If your plan does include weight-loss coverage, or if your prescription is for a different FDA-approved use, the request goes through prior authorization where documentation actually matters.
Plan-by-plan: Does Humana cover Wegovy in 2026?
The Humana × Wegovy Coverage Path Matrix (verified May 15, 2026)
| Your Humana plan | Weight loss alone | CV risk reduction (CVD + BMI ≥27) | MASH (moderate‑to‑advanced fibrosis) | Medicare GLP-1 Bridge (July 1, 2026+) | Likely cost if approved |
|---|---|---|---|---|---|
| Commercial / employer plan | ❌ Usually excluded. Some employers add weight-management coverage. | Plan-specific. Commercial plans can evaluate the FDA-approved CV indication under PA. | Plan-specific. Check formulary and PA criteria. | ❌ Not eligible (Bridge is Part D only) | If excluded: self-pay $149–$399/month |
| Medicare Advantage with Rx (MAPD) | ❌ Excluded for weight loss | ✓ Possible with PA. Prescriber submits under CV risk reduction indication. | ✓ Possible with PA. Wegovy injection only. | ✓ If you meet Bridge clinical criteria for weight management. | CV/MASH: plan-specific. Bridge: $50/month flat. |
| Standalone Medicare Part D (PDP) | ❌ Excluded for weight loss | ✓ Same as MAPD | ✓ Same as MAPD | ✓ Same as MAPD | Same as MAPD |
| Healthy Horizons Medicaid (FL, IN, KY, LA, OH, OK, SC, VA) | ⚠️ State-dependent. 13 state Medicaid programs covered GLP-1s for obesity as of Jan 2026. | Sometimes; varies by state PDL | Sometimes; varies by state PDL | ❌ Not eligible (Bridge is Medicare only) | Usually $0–$3 if covered |
| Medigap (Medicare Supplement) | N/A — Medigap doesn't cover Rx drugs | N/A — your Part D plan decides | N/A — your Part D plan decides | ✓ If your Part D plan is eligible | Determined by your Part D plan |
| EGWP (employer group waiver) | ❌ Treated like Part D — excluded for weight loss | ✓ Same as Part D | ✓ Same as Part D | ✓ EGWP members explicitly eligible for the Bridge | $50/month via Bridge if approved |
Sources: Humana 2026 Medicare Formulary PDG (updated 05/05/2026); Humana clinical policy PG194; CMS Medicare GLP-1 Bridge FAQ; FDA Wegovy prescribing information; KFF Medicaid GLP-1 coverage analysis (January 2026); Humana provider prior authorization state list.
The coverage rule almost nobody explains clearly
Federal law from 2003 bars Medicare Part D plans from covering drugs used solely for weight loss. But the law has a giant loophole: if the same drug is FDA-approved for a different reason, Part D plans can cover it for that reason.
Wegovy has now hit that loophole twice:
- March 2024: FDA approved Wegovy to reduce the risk of heart attack, stroke, and cardiovascular death in adults with existing heart disease who are overweight or obese.
- More recently: FDA approved Wegovy injection for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis in adults.
So when people ask “does Humana Medicare cover Wegovy,” the most accurate answer has four routes: not for weight loss through ordinary Part D, possible for cardiovascular risk reduction, possible for MASH if the plan criteria apply, and $50/month through the Medicare GLP-1 Bridge for qualifying weight-management use starting July 1, 2026.
Does Humana cover Wegovy for cardiovascular risk reduction?
Who qualifies for this path
You generally need three things on paper:
- Established cardiovascular disease. Per Humana's clinical policy, that means a prior heart attack, prior stroke, or symptomatic peripheral artery disease. High cholesterol or high blood pressure alone usually isn't enough.
- BMI of 27 or higher. You don't have to be obese for this pathway — overweight is enough.
- A cardiovascular diagnosis clearly documented on the prescription, not framed as weight loss. Your prescriber should submit under the FDA-approved cardiovascular risk reduction indication.
That documentation piece is where many valid claims die. Your doctor knows you have heart disease, but if their staff bills the claim as a weight-loss request, Humana's system rejects it as a weight-loss claim. Ask your doctor's office to confirm the cardiovascular indication is clearly documented before sending the prescription to the pharmacy.
What prior authorization usually requires
- Your cardiovascular diagnosis with the supporting ICD-10 code
- Your BMI history (current and recent)
- Cardiology notes confirming the CV event or condition (prior MI, prior stroke, symptomatic PAD)
- Documented lifestyle modification (diet, activity)
- Any prior medications you've tried
Your prescriber's office can submit by phone, online portal, or fax. Humana Clinical Pharmacy Review: 800-555-CLIN (2546), Monday through Friday.
What it costs even when approved
If Wegovy is covered through ordinary Part D for the CV indication, your monthly cost depends on your specific plan's tier, deductible, and coinsurance. Many plans place Wegovy on a specialty tier, which can produce coinsurance-based costs that run into the hundreds per month until you hit the 2026 Part D out-of-pocket cap of $2,100. Once you hit that cap, your covered drugs cost nothing for the rest of the calendar year.
Important: if your prescription is for cardiovascular risk reduction, the Medicare GLP-1 Bridge does not apply. CMS rules say the Bridge route is for weight-management prescriptions; CV-indication prescriptions stay with your Part D plan.
Have established cardiovascular disease?
Ro's insurance concierge can check coverage and handle prior authorization paperwork for commercial Humana plans. (Ro does not coordinate government insurance.)
Check your Wegovy coverage with Ro →Does Humana cover Wegovy for MASH or liver disease?
MASH (formerly called NASH) is a serious form of fatty liver disease where excess fat in the liver causes inflammation and scarring. Moderate-to-advanced fibrosis means the scarring has progressed but the liver isn't yet cirrhotic. Wegovy injection is now one of the very few medications FDA-approved specifically for this condition.
What prior authorization typically requires
- A documented diagnosis of noncirrhotic MASH with moderate-to-advanced fibrosis (usually staged by liver biopsy or non-invasive testing)
- A specialist confirmation, often from a hepatologist or gastroenterologist
- BMI and weight history
- Documentation that the prescription is for the MASH indication, not weight loss
The same Humana Clinical Pharmacy Review process applies (800-555-CLIN). Submission goes through your prescriber.
Important: like the CV indication, MASH coverage runs through ordinary Part D, not the Medicare GLP-1 Bridge. The Bridge is specifically for weight-management use.
The Medicare GLP-1 Bridge: $50 a month, starting July 1, 2026
(And the Humana twist nobody's talking about)
The Bridge in 30 seconds
Federal law has blocked Medicare from paying for weight-loss drugs since 2003. The Bridge is the first program to break that wall. CMS announced it on December 23, 2025 and released detailed FAQs in March 2026. Three things make it different from normal Part D coverage:
- Flat $50 copay for the whole monthly supply, regardless of your dose or formulation.
- Single central processor — Humana handles every Bridge claim for every eligible Medicare beneficiary in the country, with a special pharmacy BIN (028918) and PCN (MEDDGLP1BR).
- Your Part D plan does not have to opt in for Bridge processing. If you're enrolled in an eligible Part D plan type, meet the Bridge clinical criteria, and your prescription is for Bridge-covered weight-management use, the Bridge route may apply.
Who's eligible
You must be enrolled in a standalone PDP, MA-PD coordinated care plan, employer/union group waiver plan (EGWP), Special Needs Plan (SNP), or the LI NET program. Then you must meet one of three clinical tiers:
| Tier | Threshold |
|---|---|
| Category A — severe obesity | BMI ≥35 (no additional condition required) |
| Category B — obesity with comorbidity | BMI ≥30, plus one of: heart failure with preserved ejection fraction (HFpEF), uncontrolled hypertension (systolic >140 or diastolic >90 while on two antihypertensives), or chronic kidney disease stage 3 or higher |
| Category C — overweight with high risk | BMI ≥27, plus one of: pre-diabetes, previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease |
You don't have to currently meet the BMI threshold. CMS allows your prescriber to file an Initial-State Attestation — they confirm you met the threshold when you first started GLP-1 therapy. So if you've already lost weight on Wegovy and your BMI is now below 35, your $50 access is protected.
Covered drugs
The Bridge covers all formulations of Wegovy (injection pens and tablets), all formulations of Foundayo, and the KwikPen formulation of Zepbound only — single-dose vials and single-dose pens of Zepbound are not included.
Bridge cost traps to know about
- The $50 copay does not count toward your $2,100 Part D out-of-pocket cap.
- It also doesn't count toward your Part D deductible.
- Manufacturer coupons and discount cards cannot stack with Bridge claims.
- The Low-Income Subsidy (Extra Help) does not apply to Bridge prescriptions.
- The program ends December 31, 2027.
Can you use the Bridge if your Wegovy is for cardiovascular risk reduction?
No. Per CMS Bridge guidance, if Wegovy is prescribed for a use that is coverable under ordinary Part D — including cardiovascular risk reduction or MASH — the claim stays with the Part D plan and does not qualify for Bridge coverage. The Bridge is a separate track specifically for weight-management prescriptions.
The Humana twist
The same Humana that excludes Wegovy for weight loss on most of its own plans is the federal contractor that approves Bridge claims for everyone in the country. CMS picked Humana because it already runs the LI NET program for low-income transitions, and the infrastructure was the cleanest fit. So whether you have Humana Medicare, UnitedHealthcare Medicare, Aetna, Cigna, or any other Part D plan — your Bridge prior authorization goes to Humana.
Two takeaways: your existing Humana plan doesn't get you any advantage in the Bridge — coverage is the same for everyone. And the PA process feels different from a normal Humana decision because it's running on CMS rules, not Humana plan rules.
For the full Bridge playbook
The Medicare GLP-1 Bridge: $50/mo Through Dec 2027 →BIN/PCN details, prescriber portal, eligibility tier checklist — all in one place.
How to check your exact Humana plan for Wegovy coverage
Step 1 — Search MyHumana
Log in at humana.com → your pharmacy or drug list section → search each of these one at a time:
- Wegovy
- Wegovy pen
- Wegovy tablets
- Wegovy HD
- Semaglutide
Look for tier, prior authorization (PA), step therapy (ST), quantity limit (QL), or exclusion flags. If Wegovy doesn't appear, call to confirm.
Step 2 — Call Humana with this script
“Hi, I'd like to confirm Wegovy coverage on my exact plan. I have a few specific questions.
1. Is Wegovy on my plan's formulary for the current plan year?
2. Is it covered for my diagnosis? My diagnosis is _____ (state your reason — weight management, cardiovascular risk reduction, MASH, etc.).
3. Is prior authorization required, and if so, what specific documentation does my doctor need to submit?
4. If I'm denied, what's the most common reason — missing documentation, non-formulary status, or a plan benefit exclusion?
5. If I'm a Medicare Part D or MA-PD member with weight-management use, should this go through the CMS Medicare GLP-1 Bridge starting July 1, 2026, or through ordinary Part D?”
Step 3 — If denied, get the denial reason in writing
The difference between “PA denied because the form was incomplete” and “drug excluded as a plan benefit” is the difference between a fixable problem and a dead end. Get it in writing so you know which one you're dealing with before you spend two weeks on an appeal.
Prior authorization checklist: what to give your doctor before they submit
Print this and hand it to your prescriber:
- ▢Current diagnosis with primary ICD-10 code (cardiovascular: I25.10, I63.9, I21.x; MASH: K75.81)
- ▢BMI history at GLP-1 initiation and current
- ▢Weight history with dated measurements over the past 6–12 months
- ▢Comorbidities documented in the chart (heart disease, MASH/fibrosis, pre-diabetes, kidney disease, hypertension, prior MI, prior stroke, symptomatic PAD)
- ▢Lifestyle modification documentation — diet program, activity log, dietitian or nutrition counseling visits
- ▢Prior weight-loss medications tried and outcome (Saxenda, phentermine, Contrave, Qsymia)
- ▢Cardiology notes if pursuing the CV risk reduction indication
- ▢Hepatology / GI notes and fibrosis staging if pursuing the MASH indication
- ▢Bridge tier attestation if pursuing Medicare GLP-1 Bridge (Category A, B, or C clinical criteria)
- ▢Initial-State Attestation if you've already lost weight and your BMI is now below the threshold (Bridge only)
- ▢Prior denial letter if you're resubmitting
Humana Clinical Pharmacy Review: 800-555-CLIN (2546)
How much does Wegovy cost with Humana in 2026?
| Path | Monthly cost | Notes |
|---|---|---|
| Humana commercial, plan covers Wegovy | Plan copay or coinsurance | Wegovy Savings Card can drop to ~$25/month if commercial plan covers |
| Humana commercial, plan excludes Wegovy | Self-pay only | Savings card maxes out at $100/month off self-pay rate |
| Humana Medicare Part D, CV or MASH indication, PA approved | Plan-specific tier + coinsurance | Check MyHumana for your specialty tier and coinsurance %. 2026 OOP cap: $2,100. |
| Humana Medicare via GLP-1 Bridge (July 1, 2026+) | $50/month flat | Doesn't count toward Part D cap or deductible |
| Humana Healthy Horizons Medicaid (covering state) | Usually $0–$3 | Varies by state |
| NovoCare self-pay, Wegovy pen 0.25 or 0.5 mg, new patient | $199/month for first 2 fills | Promotional rate ends June 30, 2026 |
| NovoCare self-pay, Wegovy pen 1.0–2.4 mg standard | $349/month | All ongoing doses |
| NovoCare self-pay, Wegovy HD 7.2 mg | $399/month | Launched April 7, 2026 |
| NovoCare self-pay, Wegovy tablet 1.5 mg or 4 mg | $149/month | 4 mg ends Aug 31, 2026 (then $199) |
| NovoCare self-pay, Wegovy tablet 9 mg–25 mg | $299/month | All higher doses |
Prices verified May 15, 2026 against novocare.com Wegovy Price Guide.
What's coming after 2026
- January 1, 2027: CMS's negotiated Maximum Fair Price kicks in for the Medicare-selected drug group “Ozempic; Rybelsus; Wegovy.” CMS reports a $274 negotiated price for a 30-day equivalent supply — but your actual cost still depends on your plan's cost-sharing.
- December 31, 2027: The Medicare GLP-1 Bridge ends. What comes next depends on whether CMS launches the BALANCE Model for Part D.
Self-pay Wegovy if Humana won't cover it
If Humana says no and you're not yet Bridge-eligible, these two telehealth options ship FDA-approved Wegovy nationwide with transparent pricing. Neither requires you to negotiate with Humana.
Ro's insurance concierge handles prior authorization for commercial Humana plans and ships FDA-approved Wegovy for members who qualify. First month $39, then $149/month; annual plan $74/month. Ro does not work with government insurance (Medicare/Medicaid).
Check Wegovy pricing with Ro →Success by Sesame starts from $59/month on an annual subscription and routes members through Costco Pharmacy for competitive self-pay Wegovy pricing. No insurance required. Works for Medicare and Medicaid members who are paying out of pocket.
See Sesame Care pricing →Prices verified May 15, 2026. Ro and Sesame Care links are affiliate links.
What to do if Humana denies your Wegovy claim
| Denial reason on your letter | What it actually means | Your next move |
|---|---|---|
| Missing documentation / incomplete request | The PA form needs more proof | Ask your prescriber to resubmit with the full PA checklist above. Most likely to be fixable. |
| Wrong diagnosis or indication | The claim was coded for a non-covered use | Ask your prescriber if another FDA-approved indication applies — CV risk reduction or MASH are the most common rescue paths. |
| Not on formulary | Drug isn't on your plan's drug list | Request a formulary exception. Your doctor submits a “medically necessary” supporting statement. |
| Plan exclusion / weight-loss benefit excluded | The benefit category isn't covered at all | Appeals rarely succeed. Pivot to Bridge eligibility, switch plans at open enrollment, or move to self-pay. |
| Step therapy required | Plan wants you to try a cheaper drug first | Document what you've already tried. Ask your doctor to request a step-therapy exception with evidence of prior failures or contraindications. |
| Bridge denial | You may not meet one of the three clinical tiers, or the prescription was coded for a non-Bridge indication | Confirm tier eligibility and check if an Initial-State Attestation applies. Bridge denials go through CMS rules, not Humana's plan rules. |
Why we don't discuss compounded semaglutide on this page
This is a search for FDA-approved brand-name Wegovy and Humana insurance coverage. Compounded semaglutide is a different product made by different pharmacies under different rules. Treating them as interchangeable would mislead you about what your insurance can pay for, what the Bridge program covers, and what your doctor is actually prescribing. The Wegovy your insurance considers covering is FDA-approved Novo Nordisk product — full stop.
What real Wegovy patients are seeing
- STEP 1 trial (Wegovy 2.4 mg, 68 weeks): Average ~14.9% body weight loss in adults with obesity, no diabetes (New England Journal of Medicine, 2021)
- STEP UP trial (Wegovy HD 7.2 mg): Higher-dose Wegovy produced additional average weight reduction versus previously approved doses
- SELECT trial (CV outcomes): 20% relative reduction in major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight — the trial that supported FDA's March 2024 CV indication
- STEP 1 extension study: Participants who stopped semaglutide regained about two-thirds of their weight loss within one year (Diabetes, Obesity and Metabolism)
Wegovy safety: who should not take it
Boxed warning:
Wegovy carries a boxed warning about the potential risk of thyroid C-cell tumors. The label is based on findings in rodent studies; whether Wegovy causes thyroid tumors in humans has not been established.
Do not use Wegovy if you:
- Have had medullary thyroid carcinoma (MTC) yourself or in your family
- Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Have had a serious allergic reaction to semaglutide or any ingredient in Wegovy
Talk to your prescriber before starting if you have:
- A history of pancreatitis
- Gallbladder problems
- Kidney problems
- Diabetic retinopathy (especially if you have type 2 diabetes)
- Plans for pregnancy (FDA label: discontinue at least 2 months before a planned pregnancy)
- Pregnancy or breastfeeding
- Upcoming anesthesia or surgery (Wegovy slows stomach emptying)
- Other diabetes medications like insulin or sulfonylureas (risk of low blood sugar)
Common side effects: nausea, diarrhea, vomiting, constipation, stomach pain, and injection-site reactions.
Serious side effects that need immediate attention include severe stomach pain (possible pancreatitis), gallbladder pain or yellowing skin, severe allergic reactions, kidney problems, and changes in vision.
Source: Wegovy prescribing information, wegovy.com/prescribing-information.html. Verified May 15, 2026.
What we actually verified for this guide
We separate three kinds of claims and source each one differently.
| Claim type | Examples | Sources |
|---|---|---|
| Commercial facts (prices, plan policies, dates) | NovoCare prices, Bridge launch date, Ro membership pricing | Manufacturer, CMS, Humana, Ro official pages — verified May 15, 2026 |
| Medical/regulatory facts (FDA status, indications) | Wegovy CV indication, MASH indication, boxed warning, trial results | FDA prescribing information, peer-reviewed clinical trials, FDA announcements |
| Editorial conclusions (best path for which reader) | Which route is right for commercial Humana members | Our analysis based on the verified facts above — labeled as our recommendation, not as fact |
Our verification log
| Item | Source | Status |
|---|---|---|
| Humana point-of-sale medically accepted indication edits on several GLP-1 drugs since June 2023 | Humana medically accepted indication edit notice | ✅ Verified for listed GLP-1 drugs; Wegovy not explicitly listed in public edit notice |
| Humana Wegovy clinical policy addresses CV risk reduction or noncirrhotic MASH | Humana clinical policy PG194 | ✅ Verified May 15, 2026 |
| Wegovy FDA-approved cardiovascular indication (March 2024) | FDA press release; Wegovy prescribing information | ✅ Verified May 15, 2026 |
| Wegovy injection FDA-approved for noncirrhotic MASH with moderate-to-advanced fibrosis | FDA label / FDA announcement | ✅ Verified May 15, 2026 |
| Medicare GLP-1 Bridge July 1, 2026 launch and December 31, 2027 end date | cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge | ✅ Verified May 15, 2026 |
| Bridge $50 copay, BIN 028918, PCN MEDDGLP1BR | CMS Medicare GLP-1 Bridge FAQ | ✅ Verified May 15, 2026 |
| Humana as CMS Bridge central processor | CMS Medicare GLP-1 Bridge FAQ | ✅ Verified May 15, 2026 |
| Bridge clinical tiers (Category A, B, C) | CMS Medicare GLP-1 Bridge FAQ | ✅ Verified May 15, 2026 |
| Initial-State Attestation provision | CMS Medicare GLP-1 Bridge FAQ | ✅ Verified May 15, 2026 |
| Bridge does not apply to Wegovy when prescribed for CV risk reduction | CMS Medicare GLP-1 Bridge FAQ | ✅ Verified May 15, 2026 |
| Boxed warning for thyroid C-cell tumors; pregnancy discontinuation timing | Wegovy prescribing information | ✅ Verified May 15, 2026 |
| NovoCare self-pay pricing (May 2026) | novocare.com Wegovy Price Guide | ✅ Verified May 15, 2026 |
| Ro Body pricing ($39 first / $149 ongoing / $74 annual); government insurance limitation | ro.co/weight-loss/pricing | ✅ Verified May 15, 2026 |
| Success by Sesame pricing (from $59/month annual subscription) | sesamecare.com weight-loss program page | ✅ Verified May 15, 2026 |
| Humana Medicaid prior authorization state list (FL, IN, KY, LA, OH, OK, SC, VA) | Humana provider prior authorization lists | ✅ Verified May 15, 2026 |
| KFF: 13 state Medicaid FFS programs covered GLP-1s for obesity as of January 2026 | KFF Medicaid GLP-1 coverage analysis | ✅ Verified May 15, 2026 |
| CMS Negotiated Maximum Fair Price for Ozempic/Rybelsus/Wegovy group ($274 for 30-day equivalent supply, effective January 1, 2027) | CMS Medicare Drug Price Negotiation Program | ✅ Verified May 15, 2026 |
| Wegovy Savings Card mechanics | novocare.com/patient/medicines/wegovy/savings-offer.html | ✅ Verified May 15, 2026 |
What we did not claim
- We did not claim every Humana plan covers Wegovy.
- We did not claim every Humana plan auto-rejects Wegovy.
- We did not claim Ro or Sesame can guarantee Humana approval.
- We did not treat compounded semaglutide as equivalent to FDA-approved Wegovy.
- We did not use testimonials as proof of medical efficacy or safety claims.
Frequently asked questions
Does Humana cover Wegovy for weight loss in 2026?
For most Humana commercial, Medicare Advantage, and standalone Part D plans, no — weight-loss-only coverage is not the standard path. Limited yes on some Humana Healthy Horizons Medicaid plans in states that cover GLP-1s for obesity, and yes through the Medicare GLP-1 Bridge starting July 1, 2026 if you qualify.
Does Humana Medicare cover Wegovy?
For weight loss alone, no through ordinary Part D rules. For cardiovascular risk reduction in adults with established heart disease and BMI 27 or higher, yes — with prior authorization under Humana's Wegovy clinical policy. For MASH with moderate-to-advanced fibrosis, yes — under the same clinical policy, Wegovy injection only. For weight-management coverage through the Medicare GLP-1 Bridge, yes — $50/month starting July 1, 2026 if you meet one of three clinical tiers.
Does Humana require prior authorization for Wegovy?
When Wegovy can be covered, prior authorization is almost always required. Humana Clinical Pharmacy Review: 800-555-CLIN (2546). For Medicare Bridge coverage, the PA goes through CMS's central processor (which is also Humana) — separate process, separate rules.
What weight loss drugs does Humana cover?
For Humana Medicare, weight-loss-only drugs are generally not covered under normal Part D. Specific GLP-1 drugs may be covered for non-weight-loss FDA-approved indications: Ozempic and Mounjaro for type 2 diabetes, Wegovy for cardiovascular risk reduction or MASH, Zepbound for obstructive sleep apnea on some plans. Coverage decisions are indication-specific.
How much does Wegovy cost with Humana if approved?
Through the cardiovascular or MASH indication on Humana Medicare Part D, your monthly cost depends on your plan's tier, deductible, and coinsurance — check MyHumana for your specific plan price. Through the Medicare GLP-1 Bridge, $50/month flat. Through Humana commercial plans that cover Wegovy, plan-specific copay (often as low as $25/month with the Wegovy Savings Card).
Can I appeal a Humana Wegovy denial?
Appeals work when the denial is about medical necessity, documentation, or coding — not when it's a benefit-design exclusion. Read your denial letter carefully. If it says 'plan exclusion' or 'not a covered benefit,' appeals usually fail. If it says missing documentation, wrong coding, or step therapy, appeals often succeed with stronger paperwork.
What is the Humana Wegovy prior authorization phone number?
Humana Clinical Pharmacy Review: 800-555-CLIN (2546), Monday through Friday, 8 a.m. to 8 p.m. local time. Your prescriber can also submit by fax or through Humana's provider portal. For your plan-specific coverage questions, call the customer service number on the back of your Humana member ID card.
Does Humana Healthy Horizons Medicaid cover Wegovy?
Depends on your state. The Humana provider prior authorization list shows Healthy Horizons Medicaid plans in Florida, Indiana, Kentucky, Louisiana, Ohio, Oklahoma, South Carolina, and Virginia. KFF reports that 13 state Medicaid fee-for-service programs covered GLP-1s for obesity as of January 2026 — check your state's preferred drug list and Humana Healthy Horizons PA criteria.
Does Wegovy tablet or Wegovy HD change Humana's coverage rules?
For weight-loss-only coverage, the indication still matters more than the formulation. But formulation can matter for non-weight-loss coverage: Wegovy injection (including HD) is labeled for cardiovascular risk reduction and (for the injection only) MASH; Wegovy tablets are labeled for chronic weight management and cardiovascular risk reduction. Confirm with your prescriber and plan.
Can Ro guarantee Humana will approve my Wegovy prescription?
No telehealth provider can force any insurer to cover a drug. Ro's insurance concierge can check your coverage and submit prior authorization paperwork for commercial insurance — but Ro currently does not coordinate coverage for government insurance plans like Humana Medicare and Humana Medicaid, except for FEHB members.
Is compounded semaglutide the same as Wegovy?
No. Wegovy is an FDA-approved branded product from Novo Nordisk. Compounded semaglutide is prepared by state-licensed pharmacies under different rules and is not an FDA-approved finished drug product. Your Humana insurance considers covering FDA-approved Wegovy — not compounded semaglutide.
What happens after the Medicare GLP-1 Bridge ends in December 2027?
CMS is using the Bridge as a runway to a longer-term Medicare obesity benefit called the BALANCE Model. CMS has indicated BALANCE will not launch for Medicare Part D in 2027. After December 31, 2027, your continued Wegovy access through Medicare will depend on whether BALANCE launches in 2028 or later, whether Congress changes the underlying 2003 law, or whether you pivot to a Part D plan that lists Wegovy or to self-pay.
Still not sure which path is right for you?
The Humana × Wegovy coverage puzzle has six plan types, four indications, two federal programs, and a moving timeline. Take our free 60-second quiz and we'll match you to the right path based on your insurance, your reason for taking Wegovy, your state, and where you are in the journey.
Take the free GLP-1 matching quiz →No commitment, no email gate. A clear answer in plain English.
Ro — insurance concierge + FDA-approved Wegovy
Handles PA for commercial Humana plans. Ships Wegovy to your door. First month $39.
Related Humana and Wegovy guides
- → Does Humana Cover Zepbound? 2026 Guide
- → The Medicare GLP-1 Bridge: $50/Month Through Dec 2027
- → Does Medicare Cover Wegovy for Weight Loss? 2026
- → Wegovy Savings Card 2026: Qualify, Cost, and Enroll
- → Best Telehealth for Wegovy: 7 Options in 2026
- → Does Cigna Cover Wegovy? 2026
- → Does TRICARE Cover Wegovy? 2026
- → GLP-1 With UnitedHealthcare: Every Path in 2026